Novo Nordisk and Eli Lilly in meeting the high demand for their GLP-1 class diabetes and anti-obesity drugs, particularly Ozempic. Despite strong sales, they struggle with supply shortages, partly due to contamination at a US site and the rise of counterfeit versions. This has led to health risks and legal challenges. The shortage has prompted…